Adherence: latest news

Adherence resources

Adherence features

Adherence in your own words

Adherence news from aidsmap

More news

Adherence news selected from other sources

  • Switch from single-tablet regimen to 3 tablets works in Denmark

    Switching from an efavirenz-containing single-tablet regimen (STR) to an efavirenz containing triple-tablet regimen (TTR) to save money maintained viral suppression in Denmark. Antiretroviral-naive people who started the TTR attained the same virologic suppression rate as people who started the STR combination.

    10 July 2014 | International AIDS Society
  • ‘Appalling service’ provided by Healthcare at Home leaves patients without drugs

    Thousands of NHS patients, some seriously ill, have not received vital medicines on time because of problems at the company contracted to deliver the drugs to these patients in their own homes. The failures in the service offered by Healthcare at Home have been described by patient groups as ‘appalling’ and ‘unsafe’, and have left patients with live-threatening conditions frightened about their ability to get hold of their drugs.

    03 June 2014 | Bureau of Investigative Journalism
  • Mystery around drug adherence still plagues medical literature

    The randomized controlled trial, or RCT, represents the gold standard of interventional studies of new drugs. But how reliable are the results when it remains unknown whether subjects in the trial actually took their medicines at all? A 2007 analysis found that only 33% of 192 papers describing RCTs of oral therapies for six chronic diseases disclosed adherence results.

    13 May 2014 | Nature Medicine
  • ARVs a Bitter Pill to Swallow for Ugandan Children

    For many of the 35,500 children in Uganda on HIV treatment, daily ARVs are too much of a bitter pill to swallow, especially if they don’t understand why they need them - Uganda’s policy is not to reveal their HIV status to children until they reach 13 years of age.

    08 May 2014 | Inter Press Service
  • Long-acting HIV drugs advanced to overcome adherence challenge

    If it proves effective, long-acting antiretroviral therapy would set up a new paradigm of monthly or quarterly injectable therapy for some patients. Long-acting drug formulations could solve one of the thorniest problems in HIV management - adherence.

    08 April 2014 | Nature Medicine
  • United Healthcare To Allow HIV/AIDS Patients to "Opt-Out" of Mail-Order Prescriptions

    United Healthcare, the United States' largest health insurer, will allow patients with HIV or AIDS who have privacy or delivery concerns, or who have difficulty discussing their HIV medications over the phone, to obtain their medications from an in-network retail pharmacy rather than by mail order.

    01 April 2014 | Consumer Watchdog
  • A Patient’s Race Affects How HIV Docs Discuss Adherence

    HIV providers alter their communication methods based on the race of their patients and are more likely to discuss adherence with minorities than with whites.

    06 February 2014 | AIDSMeds
  • US: Racial gap exists when docs talk to patients about HIV meds

    Conversations between doctors and patients about taking HIV medication as prescribed may differ depending on the patient’s race or ethnicity, research shows. Providers talked more with minority patients than with whites about adherence and tended to give directives rather than engage in problem solving.

    29 January 2014 | Futurity
  • International Labour Organization: Employment crucial for successful HIV/AIDS treatment

    People living with HIV who are employed are almost 40 per cent more likely to stick to HIV treatment than those without a job, says a new ILO study released ahead of World AIDS Day.

    02 December 2013 | International Labour Organization
  • Differing Effects of Low- and High-Fat Meals on New Raltegravir Formulation

    A high-fat meal affected levels of a reformulated raltegravir tablet less than a low-fat meal, according to results of a three-period study in healthy volunteers [1]. One aim of this trial and other ongoing research is to develop a raltegravir formulation that can be dosed once daily.

    30 October 2013 | NATAP
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.